Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Correlation of RAD21 expression with clinicopathologic features (n = 94)

From: Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers

  RAD21 negative RAD21 positive P value
Age    
≤ 50 years 40 (70%) 24 (65%) 0.589
> 50 years 17 (30%) 13 (35%)  
Tumor size    
< 20 mm 29 (55%) 20 (59%) 0.706
> 20 mm 24 (45%) 14 (41%)  
Nodal status    
Negative 42 (74%) 28 (76%) 0.829
Positive 15 (26%) 9 (24%)  
Grade    
I 2 (5%) 1 (3%) 0.128
II 7 (16%) 13 (36%)  
III 34 (79%) 22 (61%)  
ERα    
Negative 22 (44%) 17 (49%) 0.677
Positive 28 (56%) 18 (51%)  
HER2 status    
Negative 46 (96%) 30 (91%) 0.366
Positive 2 (4%) 3 (9%)  
Relapse    
Negative 44 (79%) 18 (51%) 0.007
Positive 12 (21%) 17 (49%)  
BCSS    
Negative 45 (80%) 19 (54%) 0.006
Positive 11 (20%) 16 (46%)  
  1. BCSS, Breast cancer-specific survival.